Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
At Hospital/Institution:  Presbyterian - St. Luke's Medical Center
Keywords/Phrases:  leukemia
Results 1-25 of 962 for your search:
Start Over
Selinexor in Treating Younger Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 months to 21 years
Trial IDs: 13-563, NCI-2014-00936, KPT330, NCT02091245
Genetically Modified T Cells in Treating Younger Patients with Relapsed B-cell Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Under 26
Trial IDs: 13-052, NCI-2013-01076, NCT01860937
Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 80
Trial IDs: UCDCC#230, NCI-2014-00564, X05385, 322070-12, NCT01736943
6,8-Bis(benzylthio)octanoic Acid, Cytarabine, and Daunorubicin Hydrochloride in Treating Older Patients with Newly Diagnosed Acute Myeloid Leukemia
Status: Not yet active
Phase: Phase II, Phase I
Type: Treatment
Age: 60 and over
Trial IDs: CCCWFU 22115, NCI-2015-00890, IRB00033422, NCT02472626
Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia (CML) to Characterize the Efficacy and Safety of a Range of Doses
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: AP24534-14-203, NCI-2015-01086, 2014-001617-12, NCT02467270
Immune Response after Stem Cell Transplant in HIV-Positive Patients with Hematologic Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 75 and under
Trial IDs: 2212.00, NCI-2009-01244, 2212, NCT00968630
Partially-Matched Donor Stem Cell Transplant in Treating Younger Patients with High-Risk Hematologic Malignancies
Status: Active
Phase: No phase specified
Type: Treatment
Age: Not specified
Trial IDs: SCT 0813, NCI-2015-00141, CMH SCT 0813, CMH 13H11, NCT02053545
Genetically Modified T Cells in Treating Patients With B-Cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase I
Type: Treatment
Age: Not specified
Trial IDs: CRETI-NH, NCI-2012-00644, H-19384, 19384-CRETI-NH, NCT00608270, NCT00586391
DT2219 Immunotoxin in Treating Patients with Relapsed or Refractory B-Cell Leukemia or Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 12 and over
Trial IDs: 2014LS093, NCI-2015-00555, HM2014-26, NCT02370160
Donor Progenitor Cell and Natural Kill Cell Transplant in Treating Younger Patients with High-Risk Hematologic Malignancies
Status: Active
Phase: Phase II
Type: Treatment
Age: 21 and under
Trial IDs: HAPNK1, NCI-2013-00609, NCT01807611
Dietary Intervention in Preventing Acute Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplant
Status: Not yet active
Phase: Phase II
Type: Prevention, Supportive care
Age: 10 and over
Trial IDs: UMCC 2016.029, NCI-2016-01415, NCT02763033
Conventional and Regulatory T Cells in Treating Patients with Advanced Hematologic Malignancies Undergoing T Cell-Depleted Donor Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 13 to 60
Trial IDs: BMT236, NCI-2011-03025, NCT01660607
Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CLDK378AUS23, NCI-2014-02128, NCT02186821
Donor Umbilical Cord Blood Transplant After Combination Chemotherapy and Total-Body Irradiation in Treating Younger Patients With High-Risk Hematologic Malignancies
Status: Temporarily closed
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under
Trial IDs: UCBT01, NCI-2011-03700, NCT01328496
A Study to Evaluate Steroid-free Treatment for Standard-Risk aGVHD (BMT CTN 1501)
Status: Not yet active
Phase: Phase II
Type: Supportive care, Treatment
Age: Any age
Trial IDs: BMTCTN1501, NCI-2016-00996, 5U24CA076518, NCT02806947
Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation with or without Anti-Thymocyte Globulin before Donor Umbilical Cord Blood Transplant in Treating Patients with Hematologic Cancer
Status: Not yet active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 75 and under
Trial IDs: 2015LS149, NCI-2016-00768, NCT02722668
Everolimus and Bendamustine Hydrochloride in Treating Patients with Relapsed or Refractory Hematologic Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UCDCC#245, NCI-2014-01934, CRAD001NUS235T, 637004, NCT02240719
Gemtuzumab Ozogamicin in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, or Chronic Myelogenous Leukemia
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 months and over
Trial IDs: CCCWFU# 99213, NCI-2013-00965, NCT01869803
Collection and Analysis of Stored Human Samples, Specimens, or Data from Patients on Terminated Protocols
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis
Age: 18 and over
Trial IDs: 08-C-N013, NCI-2015-01186, P07268, 08CN103, 04-C-0142, NCI-08-C-N013, NCT00904514
Combination Chemotherapy in Treating Patients with Recurrent Acute Myeloid Leukemia or Recurrent Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 64
Trial IDs: 2012-1064, NCI-2013-00548, NCT01794702
Targeted Therapy in Treating Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 to 69
Trial IDs: IRB00007195, NCI-2012-01084, CA180-392, NCT01620216
Start Over